MedWatch

Cancer firm postpones FDA application in wake of contractor issues

Allarity Therapeutics, formerly known as Oncology Venture, won't apply to have its cancer drug approved by US health authorities this year, despite prior plans. Contractor glitches have forced Allarity to extend its timeline.

Departing Allarity CFO Henrik Moltke thinks it's "a shame" the company is forced to postpone its application. | Foto: Oncology Venture / PR

Denmark-based Allarity Therapeutics, which changed its name from Oncology Venture in September, will not be sending its cancer drug Dovitinib against kidney cancer for approval by the US health authority Food and Drug Administration (FDA) before the end of 2020 – even though it had planned to, writes the Swedish-listed company in an announcement.

The explanation is that the manufacturer, who is to deliver the first batch of Dovitinib to be sent in with the application, has let Allarity know it can no longer guarantee that it can provide the promised products within this calendar year.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Biontech-direktører: Derfor måtte Afrika vente på coronavacciner

Tyske Biontech vil bruge de mange corona-milliarder på at hjælpe lande i Afrika med at komme både coronavirus, malaria og turberkulose til livs, men alligevel stod kontinentet langt nede i køen, da de første coronavacciner skulle distribueres. MedWatch har spurgt hvorfor.

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier